Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protocadherin-20 (PCDH20)
- Target
- PCDH20
- Molecular classification
- Non-clustered protocadherin, Cadherin superfamily (cell adhesion molecules), δ0-protocadherin (unique subtype of δ-protocadherins)
01
Overview
Protocadherin-20 (PCDH20) is a member of the δ-subgroup of non-clustered protocadherins within the cadherin superfamily of calcium-dependent cell-adhesion proteins. It contains six extracellular cadherin domains, a transmembrane segment, and a unique cytoplasmic tail. PCDH20 is predominantly expressed in the nervous system and in certain peripheral tissues such as liver and taste buds. Functionally, it has been implicated in cell–cell adhesion, the establishment and maintenance of neuronal circuits, and suppression of tumor cell proliferation and migration, particularly through antagonism of the Wnt/β-catenin signaling pathway in hepatocellular carcinoma. While its role in sensory systems has been suggested in mice, its full function in humans and its potential clinical utility as a target remains undetermined.
- Other names
- PCDH20Protocadherin-20protocadherin 20
02
Mechanism of action
Not applicable (no known drugs target PCDH20)
03
Biological functions
Cell adhesion (potential calcium-dependent cell-adhesion protein)Neuronal connectivity/cell-cell signaling in the nervous systemRegulation of cell proliferationTumor suppressor activity (notably in hepatocellular carcinoma)Role in taste bud cell-neuron wiring (in mice)
04
Disease associations
Cancer (tumor suppressor in hepatocellular carcinoma and non-small cell lung cancer)Potential neurological involvement (based on expression in the nervous system; specific diseases not clearly established)Other (possible involvement in sensory function, e.g., taste in mice)
05
Safety considerations
Unknown (no therapeutic agents directly targeting PCDH20; no specific safety concerns described)
06
Biomarkers
Downregulation or methylation status of PCDH20 may serve as a biomarker for tumor suppressor loss in hepatocellular carcinoma and non-small cell lung cancer
Beyond the preview
Go deeper on Protocadherin-20 (PCDH20).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protocadherin-20 (PCDH20).